iBio, Inc.IBIO

iBio Inc. filed its 10-Q for the quarter ended 31 March 2026 showing revenue of $100,000 across nine months, down from $200,000 in the prior comparable period. The company reported a net loss of $7.7 million and an operating loss of $8.4 million, while burning $17 million in operating cash and holding $47.6 million in cash and equivalents. R&D expense was $3.3 million, and the diluted weighted average share count stood at 119.6 million shares, with a trailing diluted loss per share of $0.06. Assets totalled $85.8 million against liabilities of $8.3 million, leaving shareholders’ equity at $77.5 million.

iBio describes itself as a clinical-stage biotech concentrated an AI-integrated drug discovery platform to build next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat conditions. The company’s platform pages showcase 3D renderings of antibody-like structures and promise “precision biologics faster and more efficiently,” yet the latest revenue line remains a single $100,000 collaboration invoice. The contrast between the polished platform narrative and the operating ledger is now a yawning gap, with no product revenue booked and only a Phase 1 obesity trial-IBIO-600-dosed in Australia to date.

The company’s most recent filings show a programme of small, steady steps: an 8-K on 1 July 2026 announcing regulatory clearance to initiate the Phase 1 trial of IBIO-600 in Australia, a second 8-K repeating the news on 17 July 2026, and a trio of 13G/A filings in May 2026 disclosing institutional holders owning a combined 10.5% of the float. None of these disclosures alter the revenue arithmetic; they merely confirm that the company’s near-term story is still written in the future tense. The company’s website continues to feature product pages for its obesity and cardiometabolic pipeline and its AI-driven antibody platform, alongside press-style imagery and claims of regulatory milestones such as “iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia.”

The operating cash burn of roughly $1.9 million a month, combined with a zero-revenue quarter and a balance sheet that still carries $77.5 million in shareholders’ equity, raises the question of how long the runway lasts if collaboration revenue remains at pocket-money levels. The cash runway depends on the speed at which the Phase 1 trial enrols, the durability of any future collaboration agreements, and whether the AI-integrated platform ever translates into revenue that materially exceeds the current single-digit invoices.

The company’s SEC filings remain the authoritative record: the 10-Q for the period ending 31 March 2026 (https://www.sec.gov/Archives/edgar/data/1420720/000110465926059416/ibio-20260331x10q.htm), the 8-K dated 1 July 2026 (https://www.sec.gov/Archives/edgar/data/1420720/000142072026000010/ibio-20260701x8k.htm), the 8-K dated 17 July 2026 (https://www.sec.gov/Archives/edgar/data/1420720/000142072026000012/ibio-20260717x8k.htm), and the 13G/A filings disclosed on 15 May 2026 (https://www.sec.gov/Archives/edgar/data/1420720/000093583626000283/xslSCHEDULE_13G_X02/primary_doc.xml).